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abstract
PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to ﬁrst-line immunochemo-
therapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory
agent lenalidomide could increase the activity of rituximab.
METHODSA phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab
was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. Patients
received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of
cycles 2 through 5. The primary end point was progression-free survival per independent radiology review.
RESULTS A total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo
plus rituximab (n = 180). Infections (63% v 49%), neutropenia (58% v 23%), and cutaneous reactions (32% v
12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 neutropenia (50% v 13%) and
leukopenia (7% v 2%) were higher with lenalidomide plus rituximab; no other grade 3 or 4 adverse event differed
by 5% or more between groups. Progression-free survival was signiﬁcantly improved for lenalidomide plus
rituximab versus placebo plus rituximab, with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P , .001) and
median duration of 39.4 months (95% CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to
16.7 months), respectively.
CONCLUSION Lenalidomide improved efﬁcacy of rituximab in patients with recurrent indolent lymphoma, with an
acceptable safety proﬁle.
J Clin Oncol 37:1188-1199. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Non-Hodgkin lymphomas (NHLs) are mostly of B-cell
origin1 and include low-grade, indolent histologies
that usually respond to initial therapy but typically
relapse.1-4 The most common indolent NHL types,
follicular lymphoma (FL) andmarginal zone lymphoma
(MZL), account for 22% and 7% of adult NHL,
respectively.5,6 Despite being distinct entities, re-
current FL and MZL are treated similarly.7,8 Single-
agent rituximab is approved by the US Food and Drug
Administration and is commonly used as treatment of
these patients.
Lenalidomide is an immunomodulatory (IMiD) drug
that binds to the cereblon E3 ubiquitin ligase complex,
resulting in ubiquitination of the transcription factors
Aiolos and Ikaros, leading to antilymphoma effects.9,10
Preclinically, lenalidomide restored the response of
tumor-inﬁltrating lymphocytes in autologous T-cell
conjugates11 and increased natural killer cell count
and function in peripheral blood and natural killer cell
lines.12,13 Adding lenalidomide to rituximab enhanced
antibody-dependent cell-mediated cytotoxicity, im-
mune synapse formation, monocyte-mediated killing,
and direct cytotoxicity against FL cells.11,14-16
There are several treatment options, none consid-
ered curative, for patients with relapsed/refractory FL
and MZL, including chemotherapy plus anti-CD20
monoclonal antibodies and targeted agents such
as phosphatidylinositol 3-kinase inhibitors. Treatment
choice is often based on duration of response to prior
therapies, types of prior therapies, and patient
comorbidities.3,17 Rituximab monotherapy is a treat-
ment option in patients who had previously responded
to rituximab, on the basis of observations that frequent
responses can occur with rituximab retreatment.18,19
Rituximab monotherapy was commonly used in the
second-line treatment of FL (25% to 47% of patients)
according to studies in the United States and
Europe.20-22 Lenalidomide plus rituximab combination
showed clinical activity in patients with previously
treated indolent NHL in a key phase II study23 and
others24,25 demonstrating overall response rates of
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65% to 77%, complete response (CR) rates of 35% to 41%,
and median progression-free survival (PFS)/time to pro-
gression of 1 to 2 years. Recently, the lenalidomide plus
rituximab combination also showed clinical activity in a
phase III study of advanced untreated FL.26 The AUGMENT
trial (ClinicalTrials.gov identiﬁer: NCT01938001) pro-
spectively compared efﬁcacy and safety of lenalidomide
plus rituximab to placebo plus rituximab (a standard of
care, among several) in patients with relapsed or refractory
indolent NHL who are appropriate for rituximab mono-
therapy (Appendix Table A1, online only).
METHODS
Patients
Eligible patients had MZL or FL (grades 1 to 3a) requiring
treatment per investigator assessment; at least one prior
chemotherapy, immunotherapy, or chemoimmunotherapy
and two or more previous doses of rituximab; and relapsed,
refractory, or progressive disease and not rituximab-
refractory disease. Patients with neuropathy grade great-
er than one were excluded. Additional eligibility criteria are
in the Appendix (online only).
Trial Design and Treatment
Patients were randomly assigned (1:1 ratio) to lenalidomide
plus rituximab (lenalidomide plus rituximab group) or
placebo plus rituximab (placebo plus rituximab group).
Random assignment was stratiﬁed according to previous
rituximab treatment (yes or no), time since last therapy (# 2
years v. 2 years), and histology (FL vMZL). Prior induction
and maintenance treatment were considered one treat-
ment line.
Treatment continued for 12 cycles or relapse, progressive
disease, withdrawal of consent, or unacceptable toxicity.
Lenalidomide plus rituximab dosing included oral lenali-
domide 20 mg daily (10 mg for creatinine clearance 30 to
59 mL/min) on days 1 to 21 plus intravenous rituximab
375 mg/m2 days 1, 8, 15, and 22 of cycle 1 and day 1 of
cycles 2 to 5 every 28 days. Placebo plus rituximab was
administered similarly. The rituximab regimen was selected
using efﬁcacy and statistical assumptions from the LYM-
3001 trial (ClinicalTrials.gov identiﬁer: NCT00312845) in
similar patients.18 Rationale for lenalidomide and rituximab
dosing schedules are detailed in the Appendix. On treat-
ment completion or discontinuation, patients were ob-
served for progression, subsequent therapies, response to
next therapies, and second malignancies for up to 5 years
after the last patient was randomly assigned (Appendix).
Dose adjustments of lenalidomide were planned to manage
toxicity (Appendix). In patients with thromboembolism risk,
prophylactic anticoagulation or antiplatelet therapy at in-
vestigator discretion was recommended. Rituximab dose
was not reduced, but if discontinued for toxicity, lenalidomide
plus placebo continued per protocol (Data Supplement).
Growth factor use was allowed per ASCO/European Society
for Medical Oncology guidelines.27,28
This study was performed following Good Clinical Practice
per International Conference on Harmonization Guideline
E6 requirements under ethical principles in the Declaration
of Helsinki. Study conduct followed guidance of each site’s
institutional review board, independent ethics committee,
and regulatory authorities. All patients provided written
informed consent before trial enrollment.
Efﬁcacy and Safety Assessments
Primary efﬁcacy analyses were conducted in the intention-
to-treat population, deﬁned as all patients randomly
assigned, regardless of receiving trial treatment. The pri-
mary end point was PFS assessed by the independent
review committee (IRC) per 2007 International Working
Group criteria,29 without positron emission tomographic
imaging. Secondary end points included overall response
rate, CR, duration of response, overall survival (OS), event-
free survival, and time to next antilymphoma treatment.
Time to next chemotherapy treatment and histologic
transformation were exploratory end points.
Response and progression outcomes were assessed by a
blinded, independent central review using 2007 In-
ternational Working Group criteria on the basis of computed
axial tomography/magnetic resonance imaging scans.
Patients with gastric mucosa–associated lymphoid tissue
lymphoma underwent endoscopy for response evaluation.
Bone marrow biopsy was required to conﬁrm CR.
The safety analysis population included all patients re-
ceiving at least one dose of study medication. Adverse
event classiﬁcation used National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.03,
except for tumor ﬂare (graded by National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0) and tumor lysis (assessed per Cairo-Bishop Criteria).30
Statistical Analyses
The primary objective was to compare efﬁcacy in the
lenalidomide plus rituximab group versus the placebo plus
rituximab group on the basis of the primary end point of PFS
at one-sided a = 0.025 level. We hypothesized that median
PFS for lenalidomide plus rituximab would be 17.6 months,
and 11 months for placebo plus rituximab, on the basis of
previous results of rituximab monotherapy (Appendix).18
For 90% power to detect this difference with one-sided
a = 0.025 and one interim analysis for the futility at 50%
information time, a total of 193 PFS events were required.
The distribution for PFS and other time-to-event data were
estimated using the Kaplan-Meier procedure.31 A hazard
ratio (HR) with a two-sided 95% CI was estimated using the
stratiﬁed Cox proportional hazard regression model. For
binary types of secondary efﬁcacy end points, the number
and percentage of patients were tabulated by treatment
group, a stratiﬁed Cochran-Mantel-Haenszel test adjusting
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for possible confounding effects of the stratiﬁcation factors
was performed, and a P value was provided. Prespeciﬁed
subgroup analysis of PFS was also performed and HR
estimated from Cox proportional hazard regression model;
P value was generated using Fisher’s exact t test for binary
end points and log-rank test for time to event end points.
RESULTS
Patients and Trial Treatment
From February 13, 2014 through January 26, 2017, 358
patients enrolled from 97 centers in 15 countries were
randomly assigned 1:1 to lenalidomide plus rituximab (n =
178) or placebo plus rituximab (n = 180; Fig 1). Baseline
characteristics were similar (Table 1). Median age was 63
years (range, 26 to 88 years); 295 patients (82%) had FL,
and 63 (18%) had MZL. Overall, 51% had high tumor
burden per Groupe d’Etude des Lymphomes Folliculaires
(GELF) criteria. The median number of prior therapies was
one (range, one to 12), and 86 patients (24%) had three or
more prior systemic treatments. Relapse or progression
within 2 years of initial diagnosis had occurred in 117
patients (33%), and 56 (16%) were refractory to their last
regimen. Four patients had been lost to follow-up.
In the safety population, the full treatment course was
completed in 71% of patients with lenalidomide plus rit-
uximab and 61% with placebo plus rituximab. Adverse
events leading to dose interruptions were more common
with lenalidomide plus rituximab than lenalidomide plus
placebo (64% v 26%), reductions (26% v 3%), and dis-
continuations (9% v 5%). Neutropenia was the most
common adverse event leading to reduction (18%) and
interruption (39%) of lenalidomide. Dose modiﬁcations
successfully addressed neutropenia, with only ﬁve patients
(3%) discontinuing lenalidomide because of neutropenia.
Disease progression led to treatment discontinuations in 21
patients (12%) and 54 patients (30%) in the lenalidomide
plus rituximab and placebo plus rituximab groups, re-
spectively. Type 1 error was not controlled for secondary
and exploratory end points, and P values were descriptive
in nature.
Efﬁcacy
Primary end point. At the ﬁnal analysis, median follow-up
was 28.3 months, and 185 events total (progression or
death) were assessed by IRC (200 events per investigator
assessment) before censoring. The primary end point of
PFS assessed by IRC was signiﬁcantly superior in the
lenalidomide plus rituximab group (HR, 0.46; 95% CI, 0.34
to 0.62; P, .0001; Fig 2A; Table 2). Median PFS assessed
by IRC was 39.4 months (95% CI, 22.9 months to not
reached) with lenalidomide plus rituximab versus
14.1 months (95% CI, 11.4 to 16.7 months) with placebo
plus rituximab. PFS assessed by investigator also showed
superiority with lenalidomide plus rituximab versus placebo
plus rituximab (HR, 0.51; 95% CI, 0.38 to 0.69; P, .0001;
All patients
(N = 358)
Rituximab plus lenalidomide
(n = 178)
Rituximab plus placebo
(n = 180)
Rituximab plus lenalidomide
(n = 176)
Rituximab plus placebo
(n = 180)
Rituximab plus lenalidomide
(n = 124)
Rituximab plus placebo
(n = 107)
ITT patients
Safety patients
Entered follow-up
Not treated                                (n = 2)
  Died before treatment              (n = 1)
  Discontinued for AE                          (n = 1)
Discontinuations                     (n = 52)
   Progression                          (n = 21)
   Adverse event                      (n = 14)
   Withdrawal by patient          (n = 13)
   Death                                                     (n = 2)
   Other                                         (n = 2)
Discontinuations                   (n = 70)
   Progression                        (n = 54)
   Adverse event                      (n = 8)
   Withdrawal by patient         (n = 7)
   Other                                     (n = 1)
1:1
FIG 1. Lenalidomide plus rituximab and placebo plus rituximab group CONSORT diagram (ﬂow of patients from enrollment to analysis). AE, adverse event;
ITT, intention to treat.
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TABLE 1. Baseline Demographic and Disease Characteristics (ITT Population)*
Characteristic
Lenalidomide + Rituximab
(n = 178)
Placebo + Rituximab
(n = 180)
Total
(N = 358)
Median age, years (range) 64 (26-86) 62 (35-88) 63 (26-88)
Age $ 65 years 82 (46) 73 (41) 155 (43)
Male sex 75 (42) 97 (54) 172 (48)
ECOG performance status*
0 116 (65) 128 (71) 244 (68)
1 60 (34) 50 (28) 110 (31)
2 2 (1) 2 (1) 4 (1)
Positive bone marrow involvement
Yes 33 (19) 31 (17) 64 (18)
Biopsy not performed 72 (40) 69 (38) 141 (39)
Ann Arbor stage†
I or II 41 (23) 56 (31) 97 (27)
III or IV 137 (77) 124 (69) 261 (73)
Bulky disease‡ 45 (25) 49 (27) 94 (26)
High tumor burden per GELF criteria 97 (54) 86 (48) 183 (51)
Histology
FL grade 147 (83) 148 (82) 295 (82)
1 or 2 125 (70) 123 (68) 248 (69)
3a 22 (12) 25 (14) 47 (13)
MZL 31 (17) 32 (18) 63 (18)
Extranodal MZL of mucosa-associated lymphoid
tissue
14 (8) 16 (9) 30 (8)
Nodal 8 (4) 10 (6) 18 (5)
Splenic 9 (5) 6 (3) 15 (4)
Lactate dehydrogenase . ULN 43 (24) 39 (22) 82 (23)
B symptoms§ 16 (9) 12 (7) 28 (8)
FLIPI score||
0 or 1 52 (29) 67 (37) 119 (33)
2 55 (31) 58 (32) 113 (32)
3-5 69 (39) 54 (30) 123 (34)
Missing 2 (1) 1 (1) 3 (1)
No. of prior systemic antilymphoma regimens
1 102 (57) 97 (54) 199 (56)
2 31 (17) 42 (23) 73 (20)
3 25 (14) 19 (11) 44 (12)
$ 4 20 (11) 22 (12) 42 (12)
Prior rituximab treatment 152 (85) 150 (83) 302 (84)
Prior rituximab-containing chemotherapy regimen 130 (73) 129 (72) 259 (72)
Time since last antilymphoma therapy
# 2 years 89 (50) 92 (51) 181 (51)
. 2 years 89 (50) 88 (49) 177 (49)
(continued on following page)
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the median PFS was 25.3 months; 95% CI, 21.2 months to
not reached v 14.3 months; 95% CI, 12.4 to 17.7 months;
Appendix Fig A1, online only; Table 2). PFS probability at 2
years also favored lenalidomide plus rituximab (Table 2).
Post hoc subgroup analyses for PFS on the basis of prior
rituximab plus bendamustine or plus cyclophosphamide,
doxorubicin, vincristine, and prednisone showed results
consistent with those of the overall population (Appendix
Table A2, online only).
Secondary and exploratory end points. Among patients in
the lenalidomide plus rituximab versus placebo plus ritux-
imab groups, the rate of best overall response assessed by
IRC was 78% (95% CI, 71% to 83%) versus 53% (95% CI,
46% to 61%; P, .0001), with 34% (95% CI, 27% to 41%)
versus 18% (95% CI, 13% to 25%) of patients achieving CR
(P = .001; Table 2), with similar investigator-assessed re-
sults. Other secondary and exploratory time-to-event end
points assessed by IRC also showed superior results with
lenalidomide plus rituximab—response duration (Appendix
Fig A2, online only; Table 2), event-free survival (Appendix
Fig A3, online only; Table 2), time to next antilymphoma
treatment (Appendix Fig A4, online only; Table 2), time to
next chemotherapy treatment (Appendix Fig A5, online only;
Table 2), and PFS on next antilymphoma treatment (Ap-
pendix Fig A6, online only; Table 2).
Overall survival results are maturing, with an HR of 0.61
(95% CI, 0.33 to 1.13; Fig 2B; Table 2). Numerically fewer
deaths in treated patients have been observed with lena-
lidomide plus rituximab versus placebo plus rituximab (15 v
26), although the trial was not powered to detect OS dif-
ferences. Estimated 2-year survival in the lenalidomide plus
rituximab group was 93% (95% CI, 87% to 96%) versus
87% (95% CI, 81% to 92%) in the placebo plus rituximab
group. Survival for FL and MZL subgroups are shown in
Appendix Figures A7 and A8 (online only). In patients with
FL, OS results favored lenalidomide plus rituximab (HR,
0.45; 95% CI, 0.22 to 0.92; P = .02; Appendix Table A3,
online only), with 11 deaths with lenalidomide plus ritux-
imab versus 24 with placebo plus rituximab. No difference
was seen between groups in patients with MZL (HR, 2.89;
95% CI, 0.56 to 14.92), but with few events—ﬁve with
lenalidomide plus rituximab versus two with placebo plus
rituximab (Appendix Table A4, online only). Two patients
with MZL in the lenalidomide plus rituximab arm died early
after random assignment (3 days [did not receive any study
treatment] and 13 days). Estimated 2-year survival prob-
ability in FL was 95% (95% CI, 90% to 98%) with lenali-
domide plus rituximab and 86% (95% CI, 79% to 91%)
with placebo plus rituximab (Appendix Table A3). Esti-
mated 2-year survival in MZL was 82% (95% CI, 61% to
92%) with lenalidomide plus rituximab and 94% (95% CI,
77% to 98%) with placebo plus rituximab (Appendix Table
A4).
Histologic transformation occurred in two patients (in-
cidence per 100 person-years: 0.5%) with lenalidomide
plus rituximab and 10 patients (incidence per 100 person-
years: 2.5%) with placebo plus rituximab (Table 3). After
transformation, one patient in the lenalidomide plus rit-
uximab group and six in the placebo plus rituximab group
died.
Subgroup analyses. PFS improvements were consistent
with those of the overall population in all prespeciﬁed
subgroups except the MZL subgroup (Fig 3). In this subset
(n = 63), PFS was not signiﬁcantly different between the two
groups, with an unstratiﬁed HR of 1.00 (95% CI, 0.47 to
2.13), and the wide conﬁdence intervals imply the data are
uninformative. PFS results in theMZL subgroup are difﬁcult
to interpret because of the small sample size and imbal-
ance in baseline prognostic factors (Appendix Table A5,
online only).
TABLE 1. Baseline Demographic and Disease Characteristics (ITT Population)* (continued)
Characteristic
Lenalidomide + Rituximab
(n = 178)
Placebo + Rituximab
(n = 180)
Total
(N = 358)
Relapse/progression # 2 years of initial diagnosis 56 (31) 61 (34) 117 (33)
Refractory to last regimen 30 (17) 26 (14) 56 (16)
NOTE. All data are No. (%) unless otherwise stated. There were no signiﬁcant between-group differences in the characteristics evaluated at baseline.
Percentages may not sum to 100 because of rounding.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; FLIPI; Follicular Lymphoma International Prognostic Index; GELF,
Groupe d’Etude des Lymphomes Folliculaires; ITT, intention to treat; MZL, marginal zone lymphoma; ULN, upper limit of normal.
*The ECOG performance status scale ranges from 0 to 5, with higher scores indicating greater disability; a score of 0 indicates no symptoms, 1 indicates
mild symptoms, and 2 indicates moderate symptoms.
†Stages range from I to IV, with higher stages indicating more extensive disease.
‡Bulky disease was deﬁned as a tumor that was 7 cm or larger in the greatest dimension or at least three lesions 3 cm or larger in the longest diameter, as
measured by the investigator.
§B symptoms are systemic symptoms such as weight loss, night sweats, and fever.
||A FLIPI score indicates low (0 or 1), intermediate (2), or high (3 to 5) risk on the basis of a scoring system that gives one point for each of the following risk
factors: a hemoglobin level of less than 12 g/dL, more than four nodal areas (with the exception of spleen), age older than 60 years, a lactate dehydrogenase
level greater than the ULN, and Ann Arbor stage III or IV disease.
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Safety
The safety population included 176 patients who received
lenalidomide plus rituximab and 180 patients who re-
ceived placebo plus rituximab. Of these, 174 patients who
received lenalidomide plus rituximab (99%) and 173 who
received placebo plus rituximab (96%) had any-grade
adverse events within 28 days after last dose. Most
common adverse events are in Table 3. Adverse events of
any grade that occurred more frequently ($ 10% differ-
ence) with lenalidomide plus rituximab versus placebo
plus rituximab included neutropenia (58% v 22%),
constipation (26% v 14%), leukopenia (20% v 9%),
anemia (16% v 4%), thrombocytopenia (15% v 4%), and
tumor ﬂare (11% v 1%), respectively. More patients who
received lenalidomide plus rituximab (69%) had at least
one grade 3 or 4 adverse event compared with placebo
plus rituximab (32%). The increased rates of grade 3 or 4
adverse events with lenalidomide plus rituximab were
attributable primarily to increased grade 3 or 4 neu-
tropenia (50% v 13%) and leukopenia (7% v 2%). No
other grade 3 or 4 adverse events occurred in 5% or more
patients in either group. Febrile neutropenia occurred in
3% of patients with lenalidomide plus rituximab versus 1%
with placebo plus rituximab. Growth factors were ad-
ministered to 36% of the lenalidomide plus rituximab
group versus 12% in the placebo plus rituximab group.
Neutropenia was primarily managed through dose in-
terruptions and/or reductions and growth-factor support.
Only ﬁve patients had neutropenia leading to lenalidomide
discontinuation. All incidences of grade 3 or 4 neutropenia
in the lenalidomide plus rituximab group recovered to
grade 1 or less, with a median time of 9.0 days. Efﬁcacy
was similar regardless of occurrence of grade 3 or 4
neutropenia in the lenalidomide plus rituximab group on
the basis of post hoc analysis (Appendix Table A6, online
only).
Placebo plus rituximab group
Lenalidomide plus rituximab group
No. at risk:
Placebo + rituximab
Lenalidomide + rituximab
180 176 167 145 116 79 40 14 3 0
178 167 155 143 122 80 44 15 1 0
OS
 (p
ro
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bi
lit
y)
Time Since Random Assignment (months)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 6 12 18 24 30 36 42 5448
Hazard ratio for death, 0.61 (95% CI, 0.33 to 1.13)
B
Placebo + rituximab
Lenalidomide + rituximab
No. at risk:
Placebo + rituximab
Lenalidomide + rituximab
180 132 92 58 40 26 10 4 0
178 148 124 91 59 39 20 7 0
PF
S 
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bi
lit
y)
Time Since Random Assignment (months)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 6 12 18 24 30 36 42 48
Hazard ratio for progression or death 0.46 (95% CI, 0.34 to 0.62)
P < 0.0001
A
FIG 2. Progression-free survival
(PFS) and overall survival (OS) as
assessed by independent review
committee in the intention-to-treat
population: (A) progression-free sur-
vival; (B) overall survival.
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Fatal adverse events (grade 5) occurred in four patients
(1%), two in each group (lenalidomide plus rituximab:
arrhythmia and cardiopulmonary failure; placebo plus
rituximab: general physical health deterioration and
pneumonia). Among treated patients, 15 deaths (9%)
occurred in the lenalidomide plus rituximab group (ﬁve
deaths attributed to lymphoma) versus 26 (14%) with
placebo plus rituximab (18 deaths attributed to
lymphoma).
With lenalidomide plus rituximab, 45 patients (26%)
had at least one serious adverse event versus 25
(14%) with placebo plus rituximab (Appendix Table A7,
online only). Pneumonia was the most common serious
adverse event, occurring in ﬁve patients (3%) in each
group. Deep vein thrombosis occurred in three patients
(2%) in the lenalidomide plus rituximab and one patient
(1%) in the placebo plus rituximab groups; only one
incidence (lenalidomide plus rituximab group) was a
serious adverse event. Antiplatelet and anticoagulant
medication use is listed in Appendix Table A8 (online
only). Second primary cancers were reported in six
patients (3%) in the lenalidomide plus rituximab group
and 10 patients (6%) with placebo plus rituximab
(Appendix Table A9, online only). Two patients died of
second primary cancers (both placebo plus rituximab
arm).
TABLE 2. Efﬁcacy Outcomes (ITT Population)
Variable
Lenalidomide + Rituximab
(n = 178)
Placebo + Rituximab
(n = 180) Hazard Ratio (95% CI) P
Median PFS, months (95% CI)
As assessed by IRC 39.4 (22.9 to NR) 14.1 (11.4 to 16.7) 0.46 (0.34 to 0.62) , .0001
As assessed by investigator 25.3 (21.2 to NR) 14.3 (12.4 to 17.7) 0.51 (0.38 to 0.69) , .0001
PFS probability at 2 years, % (95% CI)
As assessed by IRC 58 (49 to 65) 36 (29 to 44)
As assessed by investigator 53 (45 to 61) 34 (27 to 41)
Best response, as assessed by IRC
ORR, No. (% [95% CI]) 138 (78 [71 to 83]) 96 (53 [46 to 61]) , .0001
CR, No. (% [95% CI]) 60 (34 [27 to 41]) 33 (18 [13 to 25]) .0010
PR, No. (%) 78 (44) 63 (35)
SD, No. (%) 20 (11) 55 (31)
PD/death, No. (%) 7 (4) 23 (13)
Not done/missing/no evidence of disease at baseline,
No. (%)
13 (7) 6 (3)
Best response, as assessed by investigator
ORR, No. (% [95% CI]) 141 (79 [73 to 85]) 107 (59 [52 to 67]) , .0001
CR, No. (% [95% CI]) 57 (32 [25 to 39]) 37 (21 [15 to 27]) .0119
PR, No. (%) 84 (47) 70 (39)
SD, No. (%) 22 (12) 56 (31)
PD/death, No. (%) 6 (3) 15 (8)
Not done/missing, No. (%) 9 (5) 2 (1)
Median DOR as assessed by IRC, months (95% CI) 36.6 (22.9 to NR) 21.7 (12.8 to 27.6) 0.53 (0.36 to 0.79) .0015
Median EFS as assessed by IRC, months (95% CI) 27.6 (22.1 to NR) 13.9 (11.4 to 16.7) 0.51 (0.38 to 0.67) , .0001
Median TTNLT, months (95% CI) NR (NR to NR) 32.2 (23.2 to NR) 0.54 (0.38 to 0.78) .0007
Median TTNCT, months (95% CI) NR (NR to NR) NR (NR to NR) 0.50 (0.32 to 0.78) .0017
Median PFS on next antilymphoma treatment, months
(95% CI)
NR (NR to NR) NR (NR to NR) 0.52 (0.32 to 0.82) .0046
Median OS, months (95% CI) NR (NR to NR) NR (NR to NR) 0.61 (0.33 to 1.13)
OS probability at 2 years, % (95% CI) 93 (87 to 96) 87 (81 to 92)
Histologic transformation, No. (%) 2 (1) 10 (6)
Abbreviations: CR; complete response; DOR, duration of response; EFS, event-free survival; IRC, independent review committee; ITT, intent to treat; NR,
not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTNCT, time to next
antilymphoma chemotherapy treatment; TTNLT, time to next antilymphoma treatment.
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DISCUSSION
The AUGMENT study met its primary end point; lenali-
domide plus rituximab demonstrated statistically signiﬁcant
and clinically relevant superiority in PFS over placebo plus
rituximab in patients with relapsed or refractory indolent FL/
MZL who are considered appropriate for rituximab mon-
otherapy. Lenalidomide plus rituximab, administered over
1 year, reduced risk of progression by 54% (HR, 0.46; 95%
CI, 0.34 to 0.62; P, .0001) and increased median PFS by
more than 2 years compared with rituximab monotherapy.
Efﬁcacy of the combination was also reﬂected by im-
provements in secondary and exploratory end points—
response rates, response duration, time to next treat-
ment, and time to next chemotherapy. Furthermore, PFS
improved in all prespeciﬁed subgroups (prior rituximab,
age, time since last therapy, sex, race, region, number of
prior antilymphoma regimens, stage, refractory to last
regimen, high tumor burden, chemoresistant, and unﬁt for
chemotherapy [deﬁned as age $ 70 years, or age 60 to 69
years and creatinine clearance , 60 mL/min or Eastern
Cooperative Oncology Group performance status $ 2])
except for the MZL subgroup. No difference in PFS was
observed between treatment groups in the MZL subgroup.
Although this could relate to lack of effect in this subset, the
small number of patients and imbalance in prognostic
factors between arms limit interpretation for this histology.
One limitation of this study was the differences in median
PFS seen when assessed by IRC (39.4 months) compared
with investigator assessment (25.3 months); however, HRs
and P values were similar between assessments, indicating
TABLE 3. Treatment-Emergent Adverse Events in the Safety Population ($ 10% of patients)
Adverse Event
Lenalidomide + Rituximab (n = 176) Placebo + Rituximab (n = 180)
All Grades Grade 3 or 4 All Grades Grade 3 or 4
Neutropenia* 102 (58) 88 (50) 40 (22) 23 (13)
Diarrhea 55 (31) 5 (3) 41 (23) 0
Constipation 46 (26) 0 25 (14) 0
Cough 40 (23) 1 (1) 31 (17) 0
Fatigue 38 (22) 2 (1) 33 (18) 1 (1)
Pyrexia 37 (21) 1 (1) 27 (15) 3 (2)
Leukopenia 36 (20) 12 (7) 17 (9) 3 (2)
Upper respiratory tract infection 32 (18) 2 (1) 23 (13) 4 (2)
Anemia 28 (16) 8 (5) 8 (4) 1 (1)
Headache 26 (15) 1 (1) 17 (9) 0
Infusion-related reaction 26 (15) 4 (2) 24 (13) 0
Thrombocytopenia 26 (15) 4 (2) 8 (4) 2 (1)
Asthenia 24 (14) 2 (1) 19 (11) 1 (1)
Decreased appetite 23 (13) 2 (1) 11 (6) 0
Muscle spasms 23 (13) 1 (1) 9 (5) 1 (1)
Peripheral edema 23 (13) 0 16 (9) 0
Abdominal pain 22 (13) 2 (1) 16 (9) 0
Pruritus 21 (12) 2 (1) 7 (4) 0
Nausea 20 (11) 0 23 (13) 1 (1)
Dyspnea 19 (11) 2 (1) 8 (4) 1 (1)
Rash 19 (11) 2 (1) 7 (4) 1 (1)
Tumor ﬂare 19 (11) 1 (1) 1 (1) 0
Alanine aminotransferase increased 18 (10) 3 (2) 15 (8) 1 (1)
Inﬂuenza 17 (10) 1 (1) 8 (4) 0
Vomiting 17 (10) 0 13 (7) 0
Back pain 14 (8) 0 18 (10) 0
Nasopharyngitis 13 (7) 0 18 (10) 0
NOTE. Data are given as No. (%).
*Febrile neutropenia occurred in ﬁve patients (3%) and one patient (1%) in the lenalidomide plus rituximab and placebo plus rituximab groups,
respectively; all occurrences were grade 3 or 4.
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consistency in PFS results between IRC and investigator
assessments. Another limitation was that longer treatment
duration occurred in the lenalidomide plus rituximab group;
however, this likely did not inﬂuence efﬁcacy results. No-
tably, separation of PFS Kaplan-Meier curves began early,
and PFS beneﬁts and durability of responses persisted
beyond 1 year of study treatment duration and were
consistently observed throughout the study follow-up pe-
riod. In addition, schedule of rituximab (eight doses given
over 5- to 28-day cycles) is not likely to have inﬂuenced
results; several studies showed beneﬁt of extended treat-
ment with rituximab (ie, beyond standard 4 weekly in-
fusions) in a manner that is independent of the number or
schedule of extended rituximab dosing (ie, four or more
doses every 1, 2, 3, or 6 months).18,32-35 Importantly, the
control group performed as expected on the basis of his-
torical rituximab data, with results similar to the 11-month
estimate used in the statistical plan.18,19,36
HR
0 1 2 3
Lenalidomide + rituximab
n/N
Placebo + rituximab
n/N HR (95% CI)
21/54
46/118
34/103
34/75
32/89
36/89
29/82
39/96
58/152
10/26
68/178
12/31
56/147
47/124
21/54
59/153
9/25
28/81
40/97
55/148
13/30
14/48
54/130
56/137
12/41
33/76
35/102
4/23
35/81
29/74
41/64
73/115
50/83
65/97
53/88
62/92
49/73
66/107
98/150
17/30
115/180
16/32
99/148
84/131
31/49
94/154
54/94
21/26
61/86
93/154
22/26
30/51
85/129
89/124
26/56
57/83
58/97
9/17
54/84
52/79
0.40 (0.23 to 0.67)
0.53 (0.37 to 0.77)
0.42 (0.27 to 0.65)
0.56 (0.37 to 0.85)
0.48 (0.31 to 0.75)
0.45 (0.30 to 0.69)
0.43 (0.27 to 0.68)
0.49 (0.33 to 0.73)
0.47 (0.34 to 0.66)
0.40 (0.18 to 0.89)
0.46 (0.34 to 0.62)
1.00 (0.47 to 2.13)
0.40 (0.29 to 0.56)
0.44 (0.31 to 0.63)
0.54 (0.31 to 0.94)
0.51 (0.37 to 0.71)
0.18 (0.07 to 0.45)
0.50 (0.32 to 0.79)
0.40 (0.27 to 0.61)
0.50 (0.36 to 0.70)
0.20 (0.09 to 0.44)
0.31 (0.16 to 0.59)
0.53 (0.37 to 0.74)
0.40 (0.28 to 0.56)
0.60 (0.30 to 1.20)
0.47 (0.31 to 0.73)
0.46 (0.31 to 0.71)
0.25 (0.08 to 0.83)
0.60 (0.39 to 0.91)
0.39 (0.25 to 0.62)
Subgroup
Overall
Rituximab naive
Yes
No
Age category, years
< 65
 65
Time since last antilymphoma therapy, years 
 2
> 2
Sex
Men
Women
Race
White
Other races
Region
United states
Europe
Other
No. of prior systemic antilymphoma regimens
1
> 1
Ann Arbor stage at enrollment
1-2
3-4
Prior rituximab containing chemotherapy regimen
Yes
No
Refractory to last prior regimen
Yes
No
High tumor burden (GELF)
Yes
No
Chemoresistant
Yes
No
Unfit for chemotherapy
Yes
No
Disease histology
Follicular lymphoma
Marginal zone lymphoma
FIG 3. Forest plot: subgroup analyses of progression-free survival. GELF, Groupe d’Etude des Lymphomes Folliculaires; HR, hazard ratio.
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Current treatment options for recurrent FL include ritux-
imab monotherapy, bendamustine, or other chemother-
apy alone or with obinutuzumab37 or rituximab.38 In
addition, the phosphatidylinositol 3-kinase inhibitors
idelalisib39 and copanlisib are approved for patients who
are more heavily pretreated than the patients in the
AUGMENT study.40 For many patients, the efﬁcacy/
toxicity tradeoffs of rituximab versus chemotherapy-
based or kinase inhibitor regimens are major issues.
There is clear rationale for adding lenalidomide to ritux-
imab in relapsed patients with FL,26 and in a previous
study in recurrent FL, lenalidomide plus rituximab was
superior to lenalidomide alone.23 Our data demonstrate
that lenalidomide plus rituximab offers clinically mean-
ingful efﬁcacy advantages over single-agent rituximab in
the context of the safety proﬁle. Adverse events were more
common in the lenalidomide plus rituximab group, largely
due to higher rates of grade 3 or 4 neutropenia, which was
successfully managed in most patients through dose
modiﬁcations and growth factors. Neutropenia was pre-
dictable and manageable; the modest increase in in-
fections and cutaneous reactions must be considered in
light of the signiﬁcantly greater efﬁcacy of the lenalido-
mide plus rituximab combination. In fact, more patients in
the lenalidomide plus rituximab group completed therapy
than those in the placebo plus rituximab group (71% v
61%) because of a lower rate of progression. The mag-
nitude of efﬁcacy differences between the two treatments
is clinically meaningful and suggests that lenalidomide
plus rituximab should replace rituximab monotherapy as a
standard of care for patients with relapsed or refractory
indolent NHL.
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APPENDIX Methods
The hypothesized median progression-free survival (PFS) for lenali-
domide plus rituximab was 17.6 months, on the basis of a reasonable
risk reduction (hazard ratio [HR] = 0.0625) from a median PFS ex-
pected of rituximabmonotherapy (11months). In single-arm studies of
lenalidomide plus rituximab in previously treated settings, the median
PFS has ranged from approximately 12 months to 24 months, making
17.6 months a reasonable assumption. We hypothesized that median
PFS for placebo plus rituximab would be 11 months, on the basis of
previous results of rituximab monotherapy.
The choice of the rituximab schedule took into consideration studies
showing that extended dosing of rituximab with four additional in-
fusions (total eight infusions) further improves efﬁcacy with acceptable
toxicity, which has led to the approval of four or eight doses of rituximab
in certain countries, including the United States. The totality of pub-
lished studies showed that extended dosing (ie, additional doses of
rituximab beyond standard four weekly infusions) further improves
beneﬁt in a manner that is independent of the number or schedule of
extended rituximab dosing (ie, four or more doses; every 1, 2, 3, or
6 months; Hainsworth JD, et al: J Clin Oncol 23:1088-1095, 2005; Piro
LD, et al: Ann Oncol 10:655-661, 1999).18,32,33 Lenalidomide 20 mg
was chosen based on published studies indicating that the combi-
nation of lenalidomide 20 mg with rituximab is well tolerated and active
in relapsed/refractory indolent non-Hodgkin lymphoma.23,35 In a
previous study, 25 mg lenalidomide in combination with rituximab was
not tolerated because of grade 3 tumor lysis syndrome in two out of four
patients.23
Key inclusion criteria included: age $ 18 years; histologically con-
ﬁrmed marginal zone lymphoma or grade 1, 2, or 3a follicular lym-
phoma (FL; CD20+; histology was retrospectively reviewed by an
independent panel of expert hematopathologists); previous treatment
with one or more prior systemic chemotherapy, immunotherapy, or
chemoimmunotherapy and two or more previous doses of rituximab;
documented relapsed, refractory, or progressive disease after prior
systemic therapy, and not rituximab refractory (refractory deﬁned as no
response or PD , 6 months after last rituximab dose); Eastern Co-
operative Oncology Group performance status less than or equal to 2;
and bidimensionally measurable disease with at least one nodal lesion
greater than 1.5 cm in diameter or at least one extranodal lesion greater
than 1.0 cm in both long and short diameters. Key exclusion criteria
included: histology other than FL or marginal zone lymphoma or
clinical evidence of transformed lymphoma, grade 3b FL, systemic
therapy within 28 days before cycle 1 day 1 dosing, prior use of
lenalidomide, neuropathy grade greater than one, presence or history
of CNS involvement by lymphoma, or unwillingness to take venous
thromboembolism prophylaxis if considered at risk for a thrombo-
embolic event.
Dose reductions and interruptions of lenalidomide were planned for
management of toxic effects associated with the drug. No more than
one dose reduction from one cycle to the next was permitted, and no
dose escalation was permitted at any time unless as speciﬁed. If
lenalidomide or placebo was discontinued, rituximab treatment could
continue as per protocol. The dose of rituximab could not be reduced;
if rituximab was discontinued because of toxicity, lenalidomide or
placebo was continued as per protocol. Lenalidomide was held and
restarted at the next lower dose (5-mg increments) if the event resolved
to a lower grade or discontinued as speciﬁed in the protocol. For all
grade 4 neutropenia or grade 3 neutropenia that was sustained for 7 or
more days or associated with fever (38.5°C), complete blood counts
were monitored every 7 days, growth factor use was permitted, and
lenalidomide was restarted if resolved to grade 2 or less. For throm-
bocytopenia grade 3 or greater (platelets , 50,000 cells/mm3),
complete blood counts were monitored every 7 days, and lenalidomide
was restarted if resolved to grade 2 or less. For grade 3 non-
desquamating or nonblistering rash, lenalidomide was restarted if
resolved to grade 1 or less. For grade 4 rash or any-grade desqua-
mating rash, lenalidomide was discontinued. For grade 3 or greater
tumor ﬂare reaction, investigators could initiate therapy with
nonsteroidal anti-inﬂammatory drugs, limited-duration corticosteroids,
and/or narcotic therapy, and lenalidomide was restarted if resolved to
grade 1 or less. For grade 2 allergic reaction or hypersensitivity,
lenalidomide was restarted if resolved to grade 1 or less. For grade 3 or
greater allergic reaction or hypersensitivity, lenalidomide was dis-
continued. For grade 3 or greater constipation, lenalidomide was
restarted if resolved to grade 2 or less. For grade 3 or greater vascular
access complication, anticoagulation was started and lenalidomide
was restarted at investigator’s discretion. For grade 3 peripheral
neuropathy, lenalidomide was restarted if resolved to grade 1 or less.
For grade 4 peripheral neuropathy, lenalidomide was discontinued.
For incidences of ALT or AST elevation to grade 3 or greater (. 5 3
upper limit of normal) or total bilirubin grade 2 or greater (. 1.5 3
upper limit of normal), ALT, AST, and total bilirubin were monitored
weekly, and lenalidomide was resumed at the same dose if levels
returned to baseline in 14 days or less or resumed at next lower dose
when returned to baseline if recovery was at greater than 14 days. In
the instance of clinical tumor lysis syndrome grade 2 or greater,
lenalidomide was held and restarted when resolved to grade 0.
Frequency of follow-up visits was based on disease status. For patients
who completed treatment or discontinued treatment for reasons other
than PD or relapse, overall survival and second malignancies were
assessed every 6 months, and follow-up computed tomography or
magnetic resonance imaging scans occurred every year. For patients
who discontinued treatment because of PD or relapse, overall survival,
subsequent antilymphoma therapies, and second malignancies were
assessed every 6 months.
An interim futility analysis was planned when approximately 96 pa-
tients had developed PD per independent review committee (IRC)
assessment or died (ie, PFS) during the study. The purpose of the
interim analysis was to stop the trial in case of futility.
At the time of the interim analysis (data cutoff of March 20, 2017),
approximately 96 IRC-assessed events were expected. However, after
the IRC had completed review, 137 events were identiﬁed. The futility
boundary was adjusted based on the actual number of events.
A data monitoring committee (DMC) meeting was held on May 30,
2017, in which DMCmembers reviewed unblinded efﬁcacy and safety
data. The DMC concluded that the results from the primary end points,
PFS per IRC assessment under US Food and Drug Administration
censoring rule, remained within the protocol-directed futility bound-
aries, and the adverse event proﬁle did not raise any unexpected safety
concerns. Therefore, the DMC recommended that the AUGMENT
study continue as planned.
Results
The primary analysis of PFS was based on a total of 183 events
assessed by IRC after censoring per rule suggested in US Food and
Drug Administration guidance (185 events before censoring; 200
events were assessed by investigator, 199 events after censoring). The
proportional hazards assumption was checked by introducing a
constructed time-dependent variable, that is, add to the model in-
teraction term for treatment and time. The effect of interaction term is
not signiﬁcant (data not shown). This suggests that the assumption of
proportional hazards is not violated. Prior systemic anticancer thera-
pies by regimen for both arms are listed in Appendix Table A10 (online
only).
Duration of response was superior for lenalidomide plus rituximab (HR,
0.53; 95% CI, 0.36 to 0.79; P = .015). Median duration of response
was 36.6 months (95% CI, 22.9 months to not reached) versus
21.7 months (95% CI, 12.8 to 27.6 months; Appendix Fig A2, online
only). Event-free survival was signiﬁcantly improved for lenalidomide
plus rituximab compared with placebo plus rituximab, with HR of 0.51
(95% CI, 0.38 to 0.67; P , .0001). Median event-free survival was
27.6 months (95% CI, 22.1 months to not reached) versus
13.9 months (Appendix Fig A3, online only). Time to next lymphoma
treatment was signiﬁcantly improved for lenalidomide plus rituximab
compared with placebo plus rituximab, with HR of 0.54 (95% CI, 0.38
Journal of Clinical Oncology
Lenalidomide Plus Rituximab in Recurrent Indolent Lymphoma
Downloaded from ascopubs.org by KCGG (KennisCentrum Van De Gezondheidszorg Gent) on June 11, 2019 from 193.191.170.002
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
to 0.78; P5 .0007). Median time to next lymphoma treatment was not
reached versus 32.2 months (95% CI, 23.2 months to not reached;
P 5 .0007; Appendix Fig A4, online only). Time to next antilymphoma
chemotherapy treatment was signiﬁcantly improved for lenalidomide
plus rituximab compared with placebo plus rituximab, with HR of 0.50
(95% CI, 0.32 to 0.78; P, .0017). Median time to next antilymphoma
chemotherapy treatment was not reached in either group (Appendix
Fig A5, online only). PFS on next antilymphoma treatment (PFS2) was
signiﬁcantly improved for lenalidomide plus rituximab compared with
placebo plus rituximab, with HR of 0.52 (95% CI, 0.32 to 0.82; P ,
.0046). Post hoc analysis has shown that response to subsequent
treatment was better with lenalidomide plus rituximab compared with
placebo plus rituximab (Appendix Table A11, online only). Median
PFS2 was not reached in either group (Appendix Fig A6, online only).
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FIG A1. Progression-free survival (PFS) as assessed by investigator in the intention-to-treat population.
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FIG A2. Duration of response as assessed by independent review committee in the intention-to-treat
population.
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FIG A3. Event-free survival as assessed by independent review committee in the intention-to-treat population.
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FIG A4. Time to next antilymphoma treatment in the intention-to-treat population.
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FIG A5. Time to next antilymphoma chemotherapy in the intention-to-treat population.
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FIG A6. Progression-free survival incorporating next antilymphoma treatment (PFS2) in the intention-to-treat
population.
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FIG A8. Overall survival (OS) in patients with marginal zone lymphoma in the intention-to-treat population.
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TABLE A1. List of AUGMENT Trial Investigators
Principal Investigator Site Location
Clarence S. Adoo Arizona Center for Cancer Care, 5750 W Thunderbird Rd, Suite C-300 Glendale, AZ 85306
Inci Alacacioglu Dokuz Eylul Universitesi Tip Fakultesi Hastanesi, Onkoloji Enstitusu Hematoloji Bolumu
Inciralti, 35340, Turkey
Elif Birtas Atesoglu Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hast, Hemaloji Bolumu Umuttepe
Yerleskesi, Kocaeli, 41380 Turkey
Marc Andre´ CHU UCL Mont-Godinne-Dinant asbl Avenue Dr G. Therasse Yvoir, 5530 Belgium
Irit Avivi Division of Hematology Tel Aviv Sourasky Medical Center 6 Weitzman Street Tel-Aviv, Tel-Aviv,
64239 Israel
Carlos Henrique Escosteguy Barrios União Brasileira de Educação e Assisteˆncia/Hospital São Lucas da PUCRS Avenida Ipiranga
6690 Porto Alegre, Rio Grande do Sul, 90610-000 Brazil
David Belada Fakultni nemocnice Hradee Kralove, IV Internı` Hematologicka klinika, Sokolska 581 Hradee
Kralove, Kra´love´hradecky´ kraj, 50005, Czech Republic
Dina Ben-Yehuda Hadassah Medical Organization Ein Kerem Jerusalem, Jerusalem, 91120 Israel
Pascal Bourquard Centre Hospitalier de Valence 179, BoulevardMarechal Juin, Valence Cedex 9 Valence, Rhone-
Alpes, 26953France
Sabine Brechignac Hopital Avicenne 125, rue de Stalingrad Bobigny, 93009 France
Marcelo Eduardo Zanella Capra Associação Educadora São Carlos AESC/Hospital Giovanni Battista HGB (Hospital Mãe de Deus
Center) Rua Soledade, 569 Porto Alegre, Rio Grande do Sul, 90740-340 Brazil
Susana M. Carvalho Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Servicode Hematologia Rua Prof
Lima Basto Lisboa, Lisboa, 1099-023 Portugal
Elena Pe´rez Ceballos Hospital General Universitario Morales Meseguer Servicio de Hematologia Avda. Marques de
los Velez, s/n Murcia, Murcia, 30008 Spain
Xiequn Chen The First Afﬁliated Hospital of the Fourth Military Medical University (Xijing Hospital) No. 15,
Changle Xi Road Xi’an Shanxi, 710032 China
David Clarkson University of South Alabama Mitchell Cancer Institute, Clinical Trials Department, 1660
Springhill Ave, Mobile, AL 36604
Gilberto de Freitas Colli Fundação Pio XII – Hospital de Caˆncer de Barretos Rua Antenor Duarte Vilela, 1331Barretos,
São Paulo, 14784-400 Brazil
Ugo Consoli Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi Piazza S. Maria di
Gesu`, 5 Catania, 95122 Italy
Vladmir C. Cordeiro de Lima Fundação Antoˆnio Prudente/AC Camargo Caˆncer Center Rua Professor Antoˆnio Prudente, 211
São Paulo, São Paulo, 01509-900 Brazil
Alfred DiStefano Arlington Cancer Center, 906 W Randol Mill Rd, Arlington, TX 76012
Antonio Rueda Dominguez Hospital Costa del Sol, Servicio de oncohematologia, Autovia A-7 Km 187, Marbella, Malaga,
Ma´laga, 29603 Spain
Xin Du Guangdong General Hospital No. 106 Zhongshan Second Road, GuangZhou, Guangdong,
510080 China
Charles Farber Hematology Oncology Associates of Northern New Jersey, 100 Madison Ave, 2nd ﬂoor,
Morristown, NJ 07962
Matthew Fero University of NewMexico Cancer Center, 1201 Camino ds Salud NE, Albuquerque, NM, 87106
Ian W. Flinn SCRI Tennessee Oncology Nashville, 250 25th Ave North, Suite 412 Nashville, Tennessee,
37203
Laura M. Fogliatto Hospital de Clı´nicas de Porto Alegre Rua Ramiro Barcelos, 2350 Porto Alegre, Rio Grande do
Sul, 90035-903 Brazil
Nathan H. Fowler The University of TexasMD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston,
Texas, 77030
Joaquin Sanchez Garcia Hospital Universitario Reina Soﬁa Servicio de Hematologia Avenida Menendez Pidal s/n
Cordoba, Cordoba, 14004 Spain
Bernardo Garicochea Sociedade Beneﬁcente de Senhoras do Hospital Sı´rio Libaneˆs Rua Dona Adma Jafet, 91 São
Paulo, São Paulo, 01308-050 Brazil
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TABLE A1. List of AUGMENT Trial Investigators (continued)
Principal Investigator Site Location
John Godwin Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR 97213
Andre H. Goy John Theurer Cancer Center at Hackensack UMC, 92 Second St, Hackensack, New Jersey,
07601
Ullrich Graeven Kliniken Maria Hilf GmbH Viersener Strasse 450 Mo¨nchengladbach, 41063 Germany
Sibel Hacioglu Pamukkale Uni. Tip Fakultesi Hastanesi, le Hastaliklari ABD, Fahri Goksin Onkoloji Merkezi
Hematoloji BD, Kinikli, Denizii, 20070 Turkey
Xiaonan Hong Fudan University Shanghai Cancer Center No. 270 Dong’an Road Shanghai, 200032 China
Huiqiang Huang Sun Yat Sen University Cancer Center No. 651 Dongfeng East Road, GuangZhou, Guangdong,
510060 China
Satoshi Ichikawa National University Corporation Tohoku University, Tohoku University Hospital 1-1
Seiryomachi, Aoba-ku, Sendai-shi, Miyagi, Miyagi, 980-8574 Japan
Takayuki Ishikawa Kobe City Medical Center General Hospital 2-1-1, Minatojimaminamimachi, Chuo- Ku, Kobe-
City, Hyoˆgo, 650-0047 Japan
Koji Izutsu National Cancer Center Hospital 5-1-1, Tsukiji, Chuo-ku, Tokyo, Tokyo, 104-0045 Japan
Jie Jin First Afﬁliated Hospital of Zhejiang University No. 79 Qingchun Road Hangzhou, Zhejiang,
310003 China
Tatsuro Jo The Japanese Red Cross Nagasaki Genbaku Hospital, 3-15 Morimachi, Nagasaki, Nagasaki,
852-8511, Japan
Wojciech A. Jurczak Malopolskie CentrumMedyczne S.C. Tadeusza Reytana 2 Krakow, Malopolskie, 30-510 Poland
Donald J. Jurgens Coburn Cancer Center at the St Cloud Hospital, 1900 Centracare Circle, Suite 1600, Saint
Cloud, MN 56303
Toru Kiguchi Japan Mutual Aid Association of Public School Teachers, Chugoku Central Hospital 148-13,
Kamiiwanari, Miyuki-cho, Fukuyama, Hiroshima, 720-0001 Japan
Tsutomu Kobayashi University Hospital, Kyoto Prefectural University of Medicine 465 Kajii-cho, Hirokoji-agaru,
Kawaramachi-dori, Kamigyo-ku, Kyoto-city, Kyoto, 602-8566 Japan
Zanetta Lamar Wake Forest Baptist Health, Section on Hematology and Oncology, Medical Center Blvd,
Winston-Salem, NC 27157
Paul Graf La Rose´e Schwarzwald-Baar-Klinikum Klinikstrasse 11 Villingen-Schwenningen, 78052 Germany
Ashkan Lashkari Wellness Oncology Hematology, 7320 Woodlake Ave, Suite 330, West Hills, CA 92056
Jianyong Li Jiangsu Province Hospital No, 300, Guanghzhou Road Nanjing, Jiangsu, 210029 China
Ewa Lech-Maranda Instytut Hematologii Transfuzjologii w Warszawie Indiry Gandhi 14Warszawa, Mazowieckie, 02-
776 Poland
Yosuke Minami National Cancer Center Hospital East 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577 Japan
John P. Leonard Weill Cornell Medical College–New York–Presbyterian Hospital, 520 E 70th St, New York, NY
10021
Itai Levi Soroka University Medical Center Beer-Sheva Sheva, Sheva, 84101 Israel
Jing Liu The Third Xiangya Hospital Centrel South University No. 138, Tongzipo Road Yuelu District,
Hexi, Changsha, Hunan, 410013 China
Elena Martynova Regional State Budgetary Institution of Healthcare “Regional Clinical Hospital”, Ulista Partizana
Zheleznyaka, #a, Krasnoyarsk, 660022 Russia
Jiri Mayer Fakultni nemocnice Brno, Interni Hematologicka a onkologicka klinika Jihlavska 20, Brno,
62500 Czech Republic
Heidi Mocikova Fakultni nemocnice Brno, Interni Hematologicka a onkologicka klinika Jihlavska 20, Brno,
Praha, hlavnı´ mesto, 62500 Czech Republic
Claudia Moreira Instituto Portugues de Oncologia do Porto, Francisco Gentil, Serv. Onco-Hematologia R. Dr.
Antonio Bernardino de Almeida Porto, Porto, 4200-072 Portugal
Hirokazu Nagai National Hospital Organization Nagoya Medical Center 4-1-1 Sannomaru, naka-ku, Nagoya,
Aichi, 460-0001 Japan
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TABLE A1. List of AUGMENT Trial Investigators (continued)
Principal Investigator Site Location
Silvana Novelli Hospital de la Santa CrCu I Sant Pau Servicio de hematologia c/ Sant Antoni Maria Claret, 167
Barcelona, Cataluña, 08025 Spain
Grzegorz Nowakowski Mayo Clinic, 200 First St SW, Rochester, MN 55905
Fritz Offner UZ Gent De Pintelaan 185, Gent, 9000, Belgium
Miguel Angel Islas Ohlmayer Oncology Hematology Care, 4350 Malsbary Rd, Cincinnati, OH 45242
Dorothy Pan State University of New York Upstate Medical Center, 750 East Adams St, Syracuse, NY 13210
Elena Prieto Pareja Hospital Universitario Fundacion Jimenez Diaz Servicio de Hematologia Avda. Reyes Catolicos,
2 Madrid, Madrid, 28040 Spain
Caterina Patti A.O. Ospedali Riuniti Villa Soﬁa-Cervello Via Trabucco, 180 Palermo, 90146 Italy
Semra Paydas Cukurova Universitesi Tip Fak.Balcalt Hastanesi, Ic Hastahklari AD Tibbi Onkoloji BD Adana,
01330 Turkey
Antonio Pezzutto Charite´ Universita¨tsmedizin Berlin, Campus Virchow-Klinikum Augustenburger Platz 1 Berlin,
13353 Germany
Antonio Pinto Hematology-Oncology and Stem Cell transplantation Unit, Istituto Nazionale Tumori, Fond. G.
Pascale, IRCCS, Via Semmola 52-108, Napoli, 80131 Italy
Andiara Cantarelli Boneto Pires Fundação Dr. Amaral Carvalho / Hospital Amaral Carvalho Jau´ Rua Dona Silve´ria, 150 Caixa
Postal 1038, Jau´, São Paulo, 17210-080 Brazil
Diane Prager Illinois Cancer Care P.C., 8940 N Wood Sage Rd, Peoria, IL 61615
Vadim Ptushkin GBUZ at Moscow City Clinical Hospital n.a. S.P. Botkin of department of Healthcare of Moscos
2nd Botkinsky proezd, 5, Moscow, 125284 Russia
Junyuan Qi Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences
(CAMS) No. 288 Nanjing Road Tianjin, Heping District, 300020 China
Francesca Re AOU de Parma, Via Gramsci, 14 Parma, Parma, 43100 Italy
Se´rgio Roithmann Associação Hospitalar Moinhos de Vento / Hospital Moinhos de Vento Rua Ramiro Barcelos,
910, Porto Alegre, Rio Grande do Sul, 90035-001 Brazil
Chiara Rusconi ASST Grande Ospedale Metropolitano Niguarda Piazza Ospedale Maggiore, 3 Milano, 20162
Italy
Alejandro Martin Garcia-Sancho Hospital Universitario de Salamanca Servicio de hematologia Paseo de San Vicente, 58-182
Salamanca, Salamanca, 37007 Spain
Phillip Scheinberg Real e Beneme´rita Associação Portuguesa de Beneﬁceˆncia / Hospital São Jose´ Rua Martiniano
de Carvalho, 965, São Paulo, São Paulo, 01321-001 Brazil
Adriana Alves de Souza Scheliga MS INCA HC I Hospital do Caˆncer I Praça da Cruz Vermelha, 23, Rio de Janeiro, Rio de Janeiro,
20230-130 Brazil
Sylvia Snauwaert AZ St. Jan Brugge Oostende Ruddershove 10 Brugge, 8000 Belgium
Caterina Stelitano Azienda Ospedaliera “Bianchi-Melacrino-Morelli” Via G. Melacrino 21, Reggio Calabria, Reggio
Calabria, 89100 Italy
Hang Su 307 Hospital of People’s Liberation Army (PLA), 08 Dongda Avenue Beijing, Fengtai, 100071
China
Aining Sun First Afﬁliated Hospital of Soochow University No. 188 Shizi Street Suzhou, Jiangsu, 215006
China
David A. Taber Northern Indiana Cancer Research Consortium, 3975 William Richardson Dr, South Bend, IN
46628
Agostino Tafuri Azienda Ospedaliera Sant’Andrea Via Di Grottarossa, 1035/1039, Roma, Roma, 00189, Italy
Monica Tani Ospedale Santa Maria delle Croci Viale Randi, 5 Ravenna, Ravenna, 48121 Italy
Giuseppe Tarantini ASL BAT - Ospedale Monsignor Raffaele DimiccoliVia Ippocrate, 15 Barletta, 76121 Italy
Corrado Tarella IRCCS Istituto Europeo Di Oncologia (IEO), Via Ripamonti 435 Milano, Lombardia, 20141 Italy
Adrian Tempescul Hopital Morvan-CHU Brest 5 avenue Foch Brest, 29609 France
Yasuhito Terui The Cancer Institute Hospital of Japanese Foundation for Cancer Research 3-8-31, Ariake,
Koto-ku, Tokyo, 135-8550 Japan
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TABLE A1. List of AUGMENT Trial Investigators (continued)
Principal Investigator Site Location
Catherine Thie´blemont Hopital Saint-Louis 1, Avenue Claude Vellafaux Paris, 75010 France
Marek Trneny Vseobecna fakultni nemocnice v Praze, I. Interni klinika – klinika hematologie U Nemocnice 2,
Praha, 12808 Czech Republic
Ayse Tulin Tuglular Marmara Universitesi Pendik EAH Hematoloji Bolumu, Mimar Sinan Cd. No:41 Ust Kaynarca,
Fevzicakmak Mh Pendik, Istanbul, 34890 Turkey
Gayane Tumyan Federal State Budgetary Institution “Russian Oncology Scientiﬁc Centre n.a. N.N. Blokhin”
RAMN, Kashirskoe shosse, 24, Moscow, 115478 Russia
Mehmet Turgut Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Ic Hastaliklari Anabilim Dali, Hemotoloji
Bilim Dali Kurupelit, Samsum, 55139 Turkey
Koen Van Eygen AZ Groeninge, Loofstraat 43, Kortrijk, 8500, Belgium
Jan Walewski Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Roentgena 5 Warszawa, Mazowieckie,
02-781 Poland
Douglas J. Weckstein New Hampshire Oncology Hematology, 200 Technology Dr, Hooksett, NH 03106
Go Yamamoto Toranomon Hospital 2-2-2 Toranomon, Minato-ku, Tokyo, Tokyo, 105-8470 Japan
Shenmiao Yang Peking University Peoples Hospital No. 11 Xizhimen South Ave Beijing, Xicheng, 100044 China
Rong Zhan Fujian Medical University Union Hospital No. 29, Xinquan Road Fuzhou, Fujian, 350001 China
Huilai Zhang Tianjin Medical University Cancer Institute and Hospital Huan-Hu-Xi, Ti-Yuan-Bei, Tianjin, Hexi
District, 300060 China
Daobin Zhou Peking Union Medical College Hospital No.1 Shuaifuyuan Wangfujing Beijing, Dongcheng,
100730 China
Huanling Zhu West China Hospital Sichuan University No. 37 Guoxue Alley Wuhou District, Chengdu,
Sichuan, 610041 China
Jun Zhu Beijing Cancer Hospital No. 52 Fucheng Road Beijing, Haidian, 100142 China
PierLuigi Zinzani AOU di Bologna Policlinico S. Orsola-Malpighi Via Massarenti 9 Bologna, Bologna, 40138 Italy
TABLE A2. Post hoc Subgroup Analyses for Progression-Free Survival on the Basis of Prior Treatment as Assessed by IRC
Group
Lenalidomide + Rituximab
PFS (months), Median (95% CI)
Placebo + Rituximab
PFS (months), Median (95% CI) HR (95% CI)
Total ITT population (n = 178) 39.4 (22.9 to NR) (n = 180) 14.1 (11.4 to 16.7) 0.46 (0.34 to 0.62)
Prior exposure to rituximab + bendamustine (n = 19) NR (20.2 to NR) (n = 14) 11.1 (3.0 to 30.6) 0.23 (0.06 to 0.85)
Prior exposure to rituximab + cyclophosphamide,
doxorubicin, vincristine, and prednisolone
(n = 66) 39.4 (22.1 to NR) (n = 69) 13.9 (8.7 to 28.0) 0.50 (0.30 to 0.82)
Abbreviations: HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; NR, not reached; PFS, progression-free survival.
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TABLE A3. Efﬁcacy in Patients with Follicular Lymphoma
Variable
Lenalidomide + Rituximab
(n = 147)
Placebo + Rituximab
(n = 148) HR (95% CI)* P*
Best response, as assessed by IRC
ORR, No. (% [95% CI]) 118 (80 [73 to 86]) 82 (55 [47 to 64]) , .0001
CR, No. (% [95% CI]) 51 (35 [27 to 43]) 29 (20 [14 to 27]) .0040
PR, No. (%) 67 (46) 53 (36)
SD, No. (%) 14 (10) 44 (30)
PD/death, No. (%) 7 (5) 19 (13)
Not done/missing/no evidence of disease at baseline,
No. (%)
8 (5) 3 (2)
Median PFS, as assessed by IRC, months (95% CI) 39.4 (23.1 to NR) 13.9 (11.2 to 16.0) 0.40 (0.29 to 0.56) , .0001
Median PFS, as assessed by investigator, months (95%CI) 27.8 (22.1 to NR) 13.9 (11.4 to 16.8) 0.46 (0.34 to 0.63) , .0001
Median EFS as assessed by IRC, months (95% CI) 39.4 (22.3 to NR) 13.8 (11.0 to 16.0) 0.42 (0.31 to 0.58) , .0001
Median DOR, as assessed by IRC, months (95% CI) 36.6 (24.9 to NR) 15.5 (11.2 to 25.0) 0.44 (0.29 to 0.68) .0001
Median TTNLT, months (95% CI) NR (NR to NR) 28.2 (20.8 to NR) 0.43 (0.29 to 0.65) , .0001
OS probability at 2 years, % (95% CI) 95 (90 to 98) 86 (79 to 91) 0.45 (0.22 to 0.92) .02
Deaths, No. (%) 11 (7) 24 (16)
Abbreviations: CR; complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; NR, not
reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTNLT, time to next
antilymphoma treatment.
*In subpopulation analyses, HR was estimated from Cox proportional hazard regression model, P value was obtained from Fisher exact t test for binary end
points and log-rank test for time-to-event end points.
TABLE A4. Efﬁcacy in Patients With Marginal Zone Lymphoma
Variable
Lenalidomide + Rituximab
(n = 31)
Placebo + Rituximab
(n = 32) HR (95% CI)* P*
Best response, as assessed by IRC
ORR, No. (% [95% CI]) 20 (65 [45 to 81]) 14 (44 [26 to 62]) .1313
CR, No. (% [95% CI]) 9 (29 [14 to 48]) 4 (13 [4 to 29]) .1289
PR, No. (%) 11 (35) 10 (31)
SD, No. (%) 6 (19) 11 (34)
PD/death, No. (%) 0 4 (13)
Not done/missing/no evidence of disease at baseline,
No. (%)
5 (16) 3 (9)
Median PFS, as assessed by IRC, months (95% CI) 20.2 (16.0 to NR) 25.2 (11.1 to NR) 1.00 (0.47 to 2.13) .9984
Median PFS, as assessed by investigator, months (95%CI) 19.2 (13.9 to 30.4) 22.1 (8.7 to NR) 1.04 (0.54 to 2.01) .8918
Median EFS as assessed by IRC, months (95% CI) 20.2 (14.5 to NR) 25.1 (9.2 to NR) 1.18 (0.60 to 2.29) .6324
Median DOR, as assessed by IRC, months (95% CI) 17.4 (13.2 to NR) NR (8.4 to NR) 1.81 (0.56 to 5.84) .3111
Median TTNLT, months (95% CI) 25.8 (17.7 to NR) NR (21.6 to NR) 1.58 (0.68 to 3.67) .3057
OS probability at 2 years, % (95% CI) 82 (61 to 92) 94 (77 to 98) 2.89 (0.56 to 14.92)
Deaths, No. (%) 5 (16) 2 (6)
Abbreviations: CR; complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; NR, not
reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTNLT, time to next
antilymphoma treatment.
*In subpopulation analyses, HR was estimated from Cox proportional hazard regression model, P value was obtained from Fisher exact t test for binary end
points and log-rank test for time-to-event end points.
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TABLE A5. Baseline Demographic and Disease Characteristics (ITT Population) by Histology
Characteristic
Marginal Zone Lymphoma Follicular Lymphoma Total
Rituximab +
Lenalidomide
(n = 31)
Rituximab +
Placebo
(n = 32)
Rituximab Plus
Lenalidomide
(n = 147)
Rituximab +
Placebo
(n = 148)
Rituximab +
Lenalidomide
(n = 178)
Rituximab +
Placebo
(n = 180)
Median age, years 68 66 62 61 64 62
$ 65 68 59 42 36 46 41
$ 70 42 38 23 22 26 24
Male 45 53 42 54 42 54
Ann Arbor stage IV at
enrollment
65 41 30 31 36 33
FLIPI high risk 48 25 37 31 39 30
ECOG 0 55 72 67 71 65 71
ECOG 1-2 45 28 33 29 35 29
B symptoms present 13 3 8 7 9 7
LDH elevated 29 19 23 22 24 22
Refractory to last prior
regimen
13 3 18 17 17 14
High tumor burden per
GELF (yes)
65 56 52 46 55 48
Chemoresistant 10 6 15 16 14 14
Unﬁt for chemotherapy* 48 44 27 24 30 27
NOTE. Data given as % unless otherwise noted.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; GELF, Groupe d’Etude des
Lymphomes Folliculaires; ITT, intention-to-treat; LDH, lactate dehydrogenase.
*Deﬁned as age $ 70 years, or age 60 to 69 years and creatinine clearance less than 60 mL/min or ECOG performance score greater than or equal to 2.
TABLE A6. Efﬁcacy by Occurrence of Grade 3 or 4 Neutropenia in the Safety Population
Outcome
Lenalidomide + Rituximab Placebo + Rituximab
‡ 1 Grade 3 or 4
Neutropenia (n = 88)
No Grade 3 or 4 Neutropenia
(n = 88)
‡ 1 Grade 3 or 4
Neutropenia (n = 24)
No Grade 3 or 4 Neutropenia
(n = 156)
Best response, as assessed by
IRC, No. (%)
ORR 74 (84) 64 (73) 10 (42) 86 (55)
CR 34 (39) 26 (30) 1 (4) 32 (21)
PR 40 (45) 38 (43) 9 (38) 54 (35)
SD 8 (9) 12 (14) 8 (33) 47 (30)
PD/death 3 (3) 4 (5) 6 (25) 17 (11)
Not done/missing/no evidence
of disease at baseline
3 (3) 8 (9) 0 6 (4)
Median PFS, as assessed by
IRC, months (95% CI)
NR (22.3 to NR) 39.4 (19.7 to NR) 8.3 (5.6 to 16.6) 14.3 (13.6 to 18.2)
PFS probability at 2 years, %
(95% CI)
59 (46 to 69) 57 (44 to 68) 26 (11 to 45) 38 (30 to 46)
Abbreviations: CR, complete response; IRC, independent review committee; NR, not reached; ORR, overall response rate; PFS, progression-free survival;
PR, partial response; SD, stable disease.
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TABLE A8. On-Study Use of Antiplatelet or Anticoagulant Concomitant
Medications in the Safety Population
Patients With Use of ‡ 1 Concomitant
Medications
Rituximab +
Lenalidomide
(n = 176)
Rituximab +
Placebo
(n = 180)
Antiplatelet 98 (56) 106 (59)
Anticoagulant 49 (28) 32 (18)
Antiplatelet and/or anticoagulant 123 (70) 121 (67)
NOTE. Data given as No. (%).
TABLE A7. Serious Adverse Events Occurring in Three or More Patients in Either
Group in the Safety Population
Preferred Term
Lenalidomide +
Rituximab
(n = 176)
Placebo + Rituximab
(n = 180)
Patients with$ 1 serious TEAE 45 (26) 25 (14)
Pneumonia 5 (3) 5 (3)
Febrile neutropenia 5 (3) 0
Pulmonary embolism 4 (2) 1 (1)
Sepsis 3 (2) 2 (1)
Pyrexia 3 (2) 0
Neutropenia 3 (2) 0
Pleural effusion 1 (1) 3 (2)
NOTE. Data given as No. (%).
Abbreviation: TEAE, treatment-emergent adverse event.
TABLE A9. Second Primary Malignancies in the Safety Population
Second Primary Malignancies, No. (%)
Rituximab + Lenalidomide
(n = 176)
Rituximab + Placebo
(n = 180)
Overall
(N = 356)
All second primary malignancies 6 (3) 10 (6) 16 (4)
Invasive 3 (2) 8 (4) 11 (3)
Hematologic malignancies 1 (1) 2 (1) 3 (1)
Acute myeloid leukemia 1 (1) 2 (1) 3 (1)
Solid tumor 2 (1) 6 (3) 8 (2)
Carcinoid tumor of the GI tract 1 (1) 0 1 (, 1)
Squamous cell carcinoma of lung 1 (1) 0 1 (, 1)
Adenocarcinoma of colon 0 1 (1) 1 (, 1)
Invasive ductal breast carcinoma 0 2 (1) 2 (1)
Malignant melanoma 0 1 (1) 1 (, 1)
Papillary thyroid cancer 0 1 (1) 1 (, 1)
Transitional cell cancer of the renal pelvis and ureter
localized
0 1 (1) 1 (, 1)
Noninvasive 3 (2) 3 (2) 6 (2)
Squamous cell carcinoma of skin 2 (1) 1 (1) 3 (1)
Basal cell carcinoma 1 (1) 2 (1) 3 (1)
NOTE. Data given as No. (%).
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TABLE A10. Prior Systemic Anticancer Therapies by Regimen
Prior Systemic Anticancer Therapies by Regimen
Rituximab + Lenalidomide
(n = 178)
Rituximab + Placebo
(n = 180)
Overall
(N = 358)
Rituximab monotherapy 37 (21) 42 (23) 79 (22)
R-benda 19 (11) 14 (8) 33 (9)
R-CHOP 66 (37) 69 (38) 135 (38)
R-CVP 31 (17) 26 (14) 57 (16)
Other R-chemotherapy combinations 37 (21) 41 (23) 78 (22)
O-chemotherapy 3 (2) 1 (1) 4 (1)
Single agent chemotherapy 15 (8) 16 (9) 31 (9)
Combination chemotherapy 59 (33) 56 (31) 115 (32)
Single agent targeted therapy 8 (5) 11 (6) 19 (5)
Combination targeted therapies 1 (1) 4 (2) 5 (1)
Other 7 (4) 8 (4) 15 (4)
NOTE. Data given as No. (%).
Abbreviations: O-chemotherapy, obinutuzumab plus chemotherapy; R-benda, rituximab plus bendamustine; R-chemotherapy, rituximab plus
chemotherapy; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine,
and prednisone.
TABLE A11. Response to Subsequent Treatment
Response
Rituximab +
Lenalidomide (patients
with next antilymphoma
treatment;
n = 49)
Rituximab + Placebo
(patients with next
antilymphoma treatment;
n = 80) P
ORR, No. (%)
[95% CI]
28 (57) [42 to 71] 29 (36) [26 to 48] .0282
CR, No. (%)
[95% CI]
15 (31) [18 to 45] 13 (16) [9 to 26] .0775
Abbreviations: CR, complete response; ORR, overall response rate.
Journal of Clinical Oncology
Lenalidomide Plus Rituximab in Recurrent Indolent Lymphoma
Downloaded from ascopubs.org by KCGG (KennisCentrum Van De Gezondheidszorg Gent) on June 11, 2019 from 193.191.170.002
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
